NCT01751425 2025-06-03
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
Phase 1 Terminated
Clinical Trials
15 trialsNCT04006847 2022-07-01
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT00644878 2021-08-18
MACS0254
Novartis
Phase 2 Terminated
NCT01131325 2021-05-20
MACS1148
Novartis
Phase 4 Terminated
NCT02225574 2020-02-12
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02115386 2019-12-10
MACS1532
Novartis
Phase 3 Terminated
NCT02174445 2019-12-02
DECLINE
University Hospital Freiburg
Phase 3 Terminated
NCT03079505 2019-01-23
DANIN
Hamad Medical Corporation
Phase 3 Terminated
NCT02709083 2018-11-02
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Emory University
Phase 2 Terminated
NCT02108951 2017-10-27
ENESTswift
Novartis
Phase 3 Terminated
NCT02086487 2017-03-07
NISRI
King Abdullah International Medical Research Center
Phase 4 Terminated
NCT00905398 2015-07-09
ALLPhi
Universidade Federal do Rio de Janeiro
Phase 1/2 Terminated
NCT01222143 2015-06-22
Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia
University Health Network, Toronto
Phase 1/2 Terminated
NCT00519090 2011-11-07
ENEST
Novartis
Phase 3 Terminated